Total antioxidant level is correlated with intra-ocular pressure in patients with primary angle closure glaucoma by Khaled K Abu-Amero et al.
Abu-Amero et al. BMC Research Notes 2014, 7:163
http://www.biomedcentral.com/1756-0500/7/163RESEARCH ARTICLE Open AccessTotal antioxidant level is correlated with
intra-ocular pressure in patients with primary
angle closure glaucoma
Khaled K Abu-Amero1,2*, Taif Anwar Azad1, Ahmed Mousa1, Essam A Osman1, Tahira Sultan1 and Saleh A Al-Obeidan1Abstract
Background: To evaluate total antioxidant status (TAS) in the plasma of primary angle closure glaucoma (PACG)
patients and to compare it to that of the control group. Additionally, we aim to investigate the association of
various PACG clinical indices with TAS level.
Methods: Plasma samples were obtained from 139 PACG patients and 149 glaucoma-free controls of matching
age, sex, and ethnicity. TAS in all samples was determined by spectrophotometric and enzyme-linked immunosorbent
assay methods. We studied the possible association of the TAS level with various clinical indices relevant to PACG.
Results: The mean (±SD) total antioxidant (TAS) value was almost similar in patients 1 (±0.22) compared to controls
0.97 (±0.43); p = 0.345. Among cases, mean TAS concentration showed a statistically significant lower pattern among
subjects with glaucoma onset at the age of ≤ 50 years (p = 0.037) and female subjects (p = 0.014) as well as having a
family history of glaucoma (p = 0.010). Interestingly, a statistically significant inverse correlation was detected between
TAS concentration and intra ocular pressure (IOP), (R = -0.14, p = 0.037).
Conclusions: The inverse correlation of TAS level with IOP, highlights TAS potential role as a predictive-marker for
PACG-severity.
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Although glaucoma embodies a heterogeneous group of
optic neuropathies, all types are defined by progressive and
irreversible degeneration of the optic nerve with gradual
visual field loss. Within this group, primary angle-closure
glaucoma (PACG) is a type of glaucoma characterized by a
narrow iridocorneal angle resulting in a blockage of the
aqueous outflow structures. It seems that there is an ana-
tomical and physiological predisposition to PACG. Thus,
shallow anterior chamber depth is considered an anatomic-
ally inheritable risk factor for this illness [1]. Congruently,
Eastern Asian ascendance, hyperopia and female gender
significantly predispose to this disease [2]. It has been esti-
mated that in Saudi Arabia, 40% of glaucoma patients be-
long to the PACG type [3]. This percentage is closer to* Correspondence: abuamero@gmail.com
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distribution, and reproduction in any mediumthose calculated for Asian than for European populations
[4]. Although a hereditary component for PACG exists,
causative genes have not yet been identified until recently
where a significant association at three new loci:
rs11024102 in PLEKHA7 (per-allele odds ratio (OR) =
1.22; P = 5.33 × 10(-12)), rs3753841 in COL11A1 (per-
allele OR = 1.20; P = 9.22 × 10(-10)) and rs1015213 lo-
cated between PCMTD1 and ST18 on chromosome 8q
(per-allele OR = 1.50; P = 3.29 × 10(-9) were reported
[5]. The three SNPs may explain in part some aspects
of the PACG pathogenesis, but not all. Oxidative stress
has been implicated to cause increased IOP by trigger-
ing TM degeneration and thus contributing to alter-
ations in the aqueous outflow pathway. Indeed, treatment
with hydrogen peroxide (H2O2) impairs TM cell adhesion
to the extracellular matrix and causes rearrangement of
cytoskeletal structures [6]. In humans, in vivo experimentsntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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more abundant in the TM cells of glaucoma patients.
Additionally, both increased IOP and visual field damage
were significantly related to the amount of oxidative DNA
damage affecting TM cells [6,7]. The antioxidant status of
biologic samples is regarded as an indicator of oxidative
stress, and the measurement of total antioxidant status
(TAS) is one of the most commonly used and useful pro-
cedures to test for prediction of oxidative status [8]. Here,
we investigated the total antioxidant status as a possible
contributor and potential marker for PACG.
Methods
Study population
The study adheres to the tenets of the Declaration of
Helsinki, and all participants signed an informed con-
sent. The study was approved by the College of Medicine
Ethical Committee (approval number # 08-657). Saudi
Arab participants with clinically diagnosed PACG and
healthy controls were recruited into the study at King
Abdulaziz University Hospital (KAUH) in Riyadh, Saudi
Arabia.
We recruited 139 Saudi PACG patients (cases) who
satisfied strict clinical criteria for PACG which includes
the following: at least three of the following: 1) clinical
documentation of angle closure, defined as the presence
of appositional or synnechial closure of the anterior
chamber angle involving at least 270 degrees by gonio-
scopy in either eye; 2) intraocular pressure elevated to a
level ≥21 mmHg measured by Goldmann applanation
tonometry; 3) evidence of characteristic glaucomatous
optic disk damage with excavation of the disc causing a
cup-to-disk ratio (c/d) vertically of at least 0.70 in at
least one eye; and 4) characteristic peripheral visual field
loss including nerve fiber bundle defects (nasal step, ar-
cuate scotoma, paracentral scotoma) or advanced visual
field loss (central and/or temporal island of vision) as
tested by Humphrey Field Analyzer in those patients
with vision better than 20/200 or Goldmann Manual
Perimetry in those with worse vision.
Exclusion criteria included: 1) secondary angle closure
glaucoma; 2) presence of pseudoexfoliation syndrome
even if coexistent with angle closure; 3) another cause of
optic nerve injury affecting either eye; 4) significant vis-
ual loss in both eyes not associated with glaucoma; 5) in-
ability to visualize the fundus for optic disk assessment;
or 6) refusal to participate.
Patients were recruited from the glaucoma clinic at
King Abdulaziz University Hospital (KAUH) after sign-
ing an informed consent approved by the institutional
review board (proposal number # 08-657).
A second group (n = 149) of healthy Saudi Arabs con-
trols (Controls group) free from glaucoma by examin-
ation were recruited. Entry criteria for those subjectswere age >40, normal IOP, open angles on gonioscopy,
and normal optic nerves on examination.
Plasma preparation and storage
Blood samples were collected in EDTA (ethylenedi-
aminetetraacetic acid) tubes. The tubes were centrifuged
at 5500 xg for 5 min. The plasma layer was separated
and stored at -80°C until use and the Buffy layer was
used for DNA extraction.
Plasma total antioxidant status
A widely used colorimetric-based assay available from
Randox (Randox Laboratories Ltd, UK) was used to
evaluate the plasma total antioxidant status. The assay
involves brief incubation of ABTS® (2,2′-Azinobis-di
[3-ethylbenzthiazoline sulphonate]) with peroxidase
(metmyoglobin) and hydrogen peroxide, resulting in the
generation of ABTS®+ radical cations. The method de-
tects a reduction in the generation of the ABTS®+ radical
cations by plasma antioxidants, and the decrease in the
generation of ABTS®+ radical cations is proportional to
their total antioxidant concentration. The assay was per-
formed in duplicate on an automated biochemical analyzer,
ChemWell-T (Awareness Technology Inc., FL, USA), as
per the manufacturer’s instructions (Randox Laboratories,
UK). The analyzer was programmed using a ChemWell-T
Assay Editor in the standard assay mode to add 200 μl of
chromogen (metmyoglobin and ABTS®) and 4 μl of plasma
sample/standard control/distilled water, incubate at 37°C
for 10s, and read at 630 nm. This was followed by the
addition of 40 μl of substrate (hydrogen peroxide in stabi-
lized form), incubation at 37°C for exactly 3 min, and
measuring absorbance at 630 nm. A standard control
(6-hydroxy-2,5,7,8-tetramethylchroman-2carboxylic acid)
provided in the kit (Cat. No. NX 2332: lot specific concen-
tration = 2.08 mmol/L) was used for calibration. The total
antioxidant status (TAS) was expressed as mmol/L.
Statistical analysis
Statistical analysis was performed using SPSS version
19.0 (IBM Corp., Armonk, New York, USA). Descriptive
analysis was conducted to describe the distribution of
the sample by major clinical and demographic study in-
dices. Shapiro test was applied to investigate whether
continuous variables were normally distributed. Pearson
correlation coefficient was calculated to investigate po-
tential correlations between the TAS value and different
clinical and demographic indices (Spearman test when
indicated). Student’s T test was used to compare the
mean TAS between cases and control across groups,
while Mann Whitney U test was used to compare the
mean TAS within groups (between different categories
of severity). A p-value of <0.05 was considered of
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the corresponding 95% confidence intervals.Table 2 Distribution of mean TAS level per different
categories of demographic and clinical indices
Index Category Case P value
Mean (SD)
Age (years) ≤50 0.96 (0.25) 0.297
>50 1.1 (0.22)
Gender Male 1.04 (0.2) 0.014
Female 0.95 (0.23)
Age at Onset (years) ≤50 1.33 (0.17) 0.037
>50 1.06 (0.22)
Laterality Unilateral 0.98 (0.23) 0.728
Bilateral 1.01 (0.22)
FH of Glaucoma No 1.02 (0.22) 0.010Results
In the current study, we recruited a total number of 288
subjects in the age interval of 40 years and older; where
139 subjects were of confirmed clinical diagnosis as hav-
ing PACG and were considered as cases, while other
exactly matching 149 subjects were diagnosed as glau-
coma free and were categorized in the current study as
controls. Among the cases, 85 (61.2%) were males and
54 (38.8%) were females, while among controls; 91
(61.1%) were males and 58 (38.9%) were females. Com-
paring these two gender ratios, there were not statisti-
cally different (p = 0.988). The mean (±SD) age of cases
was 63.1 (±9.4), median; 64, range [40 – 87] while the
mean (±SD) age of controls was 61.1 (±10.8), median;
60, range [40 – 93]. This minor difference in the mean age
(2 years) was not also statistically significant (p = 0.091).
The mean (±SD) total antioxidant (TAS) level was
slightly higher among cases; 1 (±0.22) than controls; 0.97
(±0.43) with a mean difference of 0.038 (95% CI: - 0.041 –
0.116] however, insignificantly (p = 0.345).
Moreover, in terms of glaucoma specific indices at the
time of presentation; family history of glaucoma was
founded in 12/139 (8.6%), while consanguinity was com-
mon among 6/139 (4.3%) of the total recruited subjects
while 7 (5%) cases were unilateral and 132 (95%) were
bilateral. The mean (±SD) age at first onset of the dis-
ease was 54.7 (±19.1), mean intraocular pressure (IOP)
was 18.2 (±7.5); where 74/139 (53.2%) subjects are under
antiglaucoma mediation, mean vertical cup/disc ratio
(CDR); 0.68 (±0.23), mean number of antiglaucoma
medications; 1.9 (±1.6), and LogMAR visual acuity; 0.65
(±0.81) (Table 1).Table 1 Cases and controls, distributed per demographic
and clinical indices at presentation
Index Category Case Control P value
No. (%) No. (%)
Gender Male 85 (61.2%) 91 (61.1%) 0.988
Female 54 (38.8%) 58 (38.9%)
Mean (SD) Mean (SD) P value
Age 63.1 (9.4) 61.1 (10.8) 0.091
TAS 1 (0.22) 0.97 (0.43) 0.345
Age at Onset 54.7 (19.1) N/A -
IOP 18.2 (7.5) N/A -
CDR 0.68 (0.23) N/A -
No. of Mediations 1.9 (1.6) N/A -
LogMAR VA 0.65 (0.81) N/A -
TAS unit of measurement is mmol/L.Meanwhile, assessment of other systemic clinical indi-
ces at presentation showed that there were a comorbid-
ity of such diseases among cases as follows: 37/139
(26.6%) were diabetic, 35/139 (25.2%) were having hyper-
tension, while hypercholesterolemia was found among 2
(1.4%) cases, coronary artery diseases in one (0.7%) case,
only two cases were smokers, in addition to 4 other mis-
cellaneous cases. Seventeen subjects (12.2%) were aware
of having glaucoma, with a mean (±SD) awareness dur-
ation of 47.1 (±42.9) months. Among the glaucoma free
group (controls): 51/149 (34.2%) were diabetic, and 54/
149 (36.2%) were suffering hypertension. There was no
statistically significant difference between cases and con-
trols neither in the prevalence of diabetes mellitus nor in
the prevalence of hypertension (p = 0.204 and 0.059
espectively).
Table 2, shows the distribution of mean TAS level per
different categories of demographic and clinical charac-
teristics. Among cases, mean TAS concentration showed
a statistically significant lower pattern among subjectsYes 0.89 (0.19)
Consanguinity No 1.01 (0.22) 0.106
Yes 0.91 (0.24)
Diabetes No 1.0 (0.22) 0.949
Yes 1.0 (0.22)
Hypertension No 0.99 (0.21) 0.258
Yes 1.03 (0.23)
IOP ≤ 21 1.02 (0.21) 0.350
> 21 0.99 (0.12)
CDR ≤ 0.65 1.03 (0.21) 0.338
> 0.65 0.99 (0.22)
No. of Medications ≤ 2 1.01 (0.23) 0.231
> 2 1.06 (0.17)
LogMAR Vision ≤ 20/60 (0.48) 0.99 (0.22) 0.136
> 20/60 (0.48) 1.04 (0.23)
TAS unit of measurement is mmol/L.
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and female subjects (p = 0.014) as well as having a family
history of glaucoma (p = 0.010). Nonetheless, there was no
association with age groups, laterality, consanguinity, IOP,
CDR, vision and numbness of antiglaucoma medication in
addition to all the other systemic characteristics (Table 2).
Investigating the potential correlation between TAS
concentration and the glaucoma indices, a statistically sig-
nificant inverse correlation was detected between TAS
concentration and IOP (R = -0.14, p = 0.037) (Figure 1).
Meanwhile, TAS concentration was not significantly cor-
related to vertical CDR (R = -0.013, p = 0.851), while the
correlation test was not applicable to other variables due
to being not normally distributed.
Discussion and conclusions
We obtained plasma samples from 139 extensively diag-
nosed PACG patients and 149 controls. Our control group
was carefully selected in terms of age, sex, ethnicity, smok-
ing status and other diseases (diabetes, hypertension and
hypercholesterolemia) which could influence TAS levels.
The two groups were matching for those factors and this
was of particular importance, as those factors can influ-
ence the TAS level, and thus can affect the results inde-
pendent of the glaucoma status [9].
We then proceeded with measurement of TAS levels
in both groups. Although TAS level was higher in the
Patient group compared to the controls, this difference
was not statistically significant. This was in contrast toFigure 1 Correlation between IOP and TAS concentration.our previous results where TAS level was decreased in a
group of patients with psueduoexfoliation glaucoma
(PEG) [10]. This may indicate that oxidative stress repre-
sented indirectly by the TAS levels, play a bigger role in
case of PEG than for PACG. Oxidative stress which is
linked strongly to mitochondrial abnormalities (such as
decreased mitochondrial respiration, mtDNA mutations
and mtDNA copy number alterations) were demon-
strated in POAG and PEG cases but not in PACG, thus
enforcing our current observation that oxidative stress
may play a minor role in PACG development compared
to other types of glaucoma. It is also possible that TAS
decreased levels are more linked to particular clinical in-
dices important for PACG rather than for the disease as
a whole. Optic nerve injury in PACG has been attributed
primarily to elevated IOP caused by anatomic changes in
the anterior [11] and posterior [12] globe, in contrast
with the molecular and biochemical abnormalities sus-
pected in POAG [13]. Perhaps for this reason, the role
of oxidative stress in PACG has received limited atten-
tion demonstrated by the fact that this is the first study
to investigate the TAS level in PACG patients. This is
despite reports that PACG may be present in 3.9 million
people around the world [14].
When we investigated the potential correlation be-
tween TAS and glaucoma indices, we found a statisti-
cally significant inverse correlation between TAS and
IOP. This is interesting, since optic nerve injury in
PACG is attributed primarily to elevated IOP.
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antioxidant activity in serum and aqueous humor in
glaucoma patients. Yildrim and colleagues studied 40 pa-
tients with glaucoma and found no association between
glaucoma and systemic myeloperoxidase or catalase en-
zyme activity [15]. Yuki and colleagues found an in-
crease in the serum total antioxidant status of patients
with normal-tension glaucoma compared to matching
controls [16]. In contrast, Sorkhabi et al. showed that
the serum level of TAS in patients with primary open
angle glaucoma was lower than that of cataract controls
[17]. Gherghel and colleagues [18] concluded that glau-
coma patients exhibit low levels of circulating glutathione,
suggesting compromised oxidative defense. The only
study of total reactive antioxidant potential (TRAP) and
antioxidant enzymes in aqueous humor was performed by
Ferreira and colleagues, and showed significantly de-
creased TRAP values and increased superoxide dismutase
and glutathione peroxidase activity in glaucoma patients
[8]. The antioxidant defense system comprises a variety of
molecules: enzymes such as superoxide dismutase, cata-
lase, or glutathione peroxidase, that are capable of catalyt-
ically removing free radicals and other reactive species;
proteins, such as transferrins or haptoglobins, that
minimize the availability of pro-oxidants such as iron
or copper ions; heat shock proteins that protect bio-
molecules against damage; and low-molecular mass
molecules such as α-tocopherol, ascorbic acid, or
glutathione capable of scavenging ROS and RNS. The
composition of antioxidant defenses differs from tissue
to tissue and from cell type to cell type [19]. All of
these compounds and more exist in human plasma.
Antioxidants that can be found in human plasma vary,
and can be summarized mainly in the following com-
pounds: albumin, ceruloplasmin, ferritin, ascorbic acid,
α-tocopherol, β-carotene, lycopene, reduced glutathione,
bilirubin, glutathione peroxidase, uric acid, catalase, and
superoxide dismutase [20]. The exact mechanism of how
oxidative stress contributes to glaucoma pathogenesis re-
mains speculative. Glaucomatous optic neuropathy implies
loss of retinal ganglion cells, including their axons, and a
major tissue remodeling, especially in the optic nerve head.
Although increased intraocular pressure is a major risk fac-
tor for glaucomatous optic neuropathy, there is little doubt
that other factors such as ocular blood flow play a role as
well [21]. Mechanisms leading to glaucomatous optic neur-
opathy are not yet clearly understood. There is, however,
increasing evidence that both an activation of glial cells
and oxidative stress in the axons may play an important
role [22]. Glial cells may be activated by mechanical stress
via activation of the epidermal growth-factor receptor, or
by ischemic stress via an increase in endothelin.
We have to acknowledge the following limitations in
our study. First, our total antioxidants method employedhere measured the total antioxidant status and not a
particular compound or byproduct. A detailed examin-
ation of those individual antioxidants separately might
help to identify a particular antioxidant that is severely
decreased and thus provide a new therapeutic agent for
glaucoma. Second, the systemic decrease in antioxidants
might not reflect the exact situation at the anterior
segment structures, which are exposed to free radicals
and thus more directly involved in the formation and
development of glaucoma through the oxidative stress
mechanism.
Since measurement of TAS levels in the plasma is usu-
ally straightforward and relatively not expensive, TAS
level can be used routinely as a marker for PACG espe-
cially if our results are confirmed in different ethnicities
and larger cohorts.
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